Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Halozyme Therapeutics reported revenue of $298.01 million for the quarter ended December 2024, marking a year-over-year increase of 29.6% and an EPS of$ 1.26 compared to $0.82 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of$ 284.02 million, resulting in a surprise of +4.93%, while the EPS also surpassed the consensus estimate of $1.16 with a surprise of +8.62% [1] Revenue Breakdown - Product sales, net amounted to$ 79.36 million, slightly below the average estimate of $75.16 million, reflecting a year-over-year change of -0.3% [4] - Royalties generated$ 170.42 million, exceeding the average estimate of $159.68 million, and showing a significant year-over-year increase of +39.6% [4] - Revenues from collaboration agreements reached$ 48.23 million, slightly below the average estimate of $49.20 million, but representing a substantial year-over-year increase of +69.9% [4] Stock Performance - Over the past month, shares of Halozyme Therapeutics have returned +6.4%, outperforming the Zacks S&P 500 composite's +4.7% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]